Quantum Biopharma Ltd QNTM.CD is expected to show a rise in quarterly revenue when it reports results on November 7 for the period ending December 31 2025
The Toronto Ontario-based company is expected to report revenue of $2.2 million, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Quantum Biopharma Ltd is for a loss of 22 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Quantum Biopharma Ltd is $40.25, about 78.7% above its last closing price of $8.59
This summary was machine generated November 7 at 22:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)